Home
Market Research
TF Market Research
more from
TF Market Research
ASTELLAS PHARMA
178 page report published Jun 30, 2008
Price
$3,240.00
,
add to your cart
This report is also available for purchase on a
per-page basis
.
Report Overview
Purchase by Section
Search Inside
About TF Market Research
... Espicom Business Intelligence June #### ii[This page left intentionally blank] Espicom Business Intelligence iiiJune #### ...
Source:
ESPICOM HEALTHCARE INTELLIGENCE
Company:
ASTELLAS PHARMA EUROPE LTD
Geographic Regions:
EUROPE
,
UNITED KINGDOM
, WESTERN EUROPE
Non-Billable Page Numbers:
1;2;3;4;5;6;9;10;33;34;142;143;144;176;177;178
Format:
PDF
Sections
Title
Starting Page
Number of Pages
Astellas Pharma
7
1
Company Information
7
1
Summary
8
1
EXECUTIVE SUMMARY
11
1
INTRODUCTION
11
1
CURRENT FINANCIAL POSITION
12
1
Company Performance
12
1
Business Segment Performance
12
3
Geographic Segment Performance
14
3
COMPANY STRATEGY
20
1
R&D Strategy
20
2
Mergers, Acquisitions and Divestitures
21
2
Key Agreements
23
1
Production
24
1
Employees
24
2
PRODUCT PERFORMANCE FORECASTS
26
2
PIPELINE ANALYSIS
28
1
Key R&D Projects
28
2
Discontinued Projects
29
2
CONCLUSIONS
31
2
THERAPEUTIC AREA FOCUS
35
1
R&D PIPELINE
36
1
CARDIOVASCULAR
38
1
MARKETED PRODUCTS
38
1
Adenocard
38
2
Adenoscan
39
2
Cibenol
40
2
Dorner
41
2
Careload LA Tablets (beraprost-MR 60mcg) for long-acting treatment of pulmonary arterial hypertension (PAH) - Market
42
1
Frandol
43
2
Hypoca/Cyress
44
1
Lexiscan
45
1
Lipitor
46
3
Micardis
48
5
Milrila
52
1
Nivadil
53
2
Perdipine
54
2
Solinase
55
2
Vaprisol
56
2
R&D PROJECTS
58
1
ASP 1517
58
1
ASP1585
58
1
Vernakalant
58
4
YM150
61
1
YM311
61
1
GROWTH FORECAST
62
1
UROLOGY
63
1
MARKETED PRODUCTS
63
1
Harnal/Omnic/Flomax
63
4
Omnic-OCAS as a once-daily controlled-release tablet - Market Data
64
1
Harnal D Tablet 0.1mg/0.2mg (WOWTAB an orally-disintegrating tablet) for functional symptoms with BPH - Market Data
64
1
Vesicare
67
2
Overactive bladder in a once-daily tablet formulation - Market Data
68
1
R&D PROJECTS
69
1
YM178
69
1
GROWTH FORECAST
70
1
INFLAMMATION & IMMUNOLOGY
71
1
MARKETED PRODUCTS
71
1
Atock/Foradil
71
1
Celecox
72
2
Intal
74
2
Prograf
75
6
R&D PROJECTS
81
1
AGI-1096
81
1
ASK 8007
81
1
ASP015K
81
1
GROWTH FORECAST
82
1
GASTROINTESTINAL
83
1
MARKETED PRODUCTS
83
1
Colonel (HSR 237)
83
1
Ganaton
83
1
Gaster/Pepcid
84
3
Tablet formulation of famotidine for heartburn - Market Data
84
1
WOWTAB (orally-disintegrating tablet) formulation, Gaster OD, for stomach ulcers - Market Data
85
1
Nasea
87
1
A WOWTAB (orally-disintegrating tablet) formulation, Nasea OD - Market Data
87
1
Once-daily tablet for diarrhoea-predominant irritable bowel syndrome in males (as Irribow) - Market Data
87
1
R&D PROJECTS
89
1
YM443
89
1
GROWTH FORECAST
90
1
INFECTIOUS DISEASE
91
1
MARKETED PRODUCTS
91
1
Aimmugen
91
1
AmBisome
91
3
Cefamezin
93
2
Cefspan
94
2
Cefzon/Omnicef
95
3
Funguard/Mycamine
97
4
Geninax
100
2
Infergen/Advaferon
101
2
Targocid
102
1
R&D PROJECTS
103
1
ASP2151
103
1
Telavancin
103
3
GROWTH FORECAST
106
1
CENTRAL NERVOUS SYSTEM
107
1
MARKETED PRODUCTS
107
1
Dogmatyl
107
2
Luvox
108
2
Myslee
110
2
Seroquel
111
3
R&D PROJECTS
115
1
ACR16
115
1
ASP2314
115
1
ASP2535
115
1
ASP2905
116
1
ASP8825
116
2
GROWTH FORECAST
118
1
DERMATOLOGY
119
1
MARKETED PRODUCTS
119
1
Amevive
119
1
Protopic
120
5
R&D PROJECTS
125
1
GROWTH FORECAST
126
1
METABOLIC
127
1
MARKETED PRODUCTS
127
1
Starsis
127
2
R&D PROJECTS
129
1
ASP9831
129
1
YM543
129
1
GROWTH FORECAST
130
1
BONE DISORDERS
131
1
MARKETED PRODUCTS
131
1
InductOs
131
1
R&D PROJECTS
133
1
Minodronate
133
1
GROWTH FORECAST
135
1
ONCOLOGY
136
1
MARKETED PRODUCTS
136
1
Eligard
136
2
SMANCS
137
2
R&D PROJECTS
139
1
AGS-16M18
139
1
AGS-8M4
139
1
ASP0265
139
1
Degarelix
139
1
YM155
139
2
GROWTH FORECAST
141
1
APPENDIX
145
1
APPENDIX 1 - FINANCIAL PERFORMANCE
145
1
APPENDIX 2-KEY CORPORATE EVENTS
148
1
APPENDIX 3-KEY AGREEMENTS
149
1
Ajinomoto Co Inc
149
1
American BioScience Inc (ABS)
149
1
AtheroGenics Inc
149
1
Biogen Idec
150
1
Boehringer Ingelheim (BI)
150
1
Cardiome Pharma Corp
150
2
Carlsson Research AB
152
1
Cephalon Inc
152
1
CoMentis Inc
152
1
CV Therapeutics Inc (CVT)
152
2
Ferring Pharmaceuticals
153
1
FibroGen Inc
153
2
Gilead Sciences Inc
154
1
GlaxoSmithKline
154
2
Gloucester Pharmaceuticals Inc
155
1
Icagen Inc
156
1
Ilypsa Inc
156
2
Immuno-Biological Laboratories
157
1
Kirin Brewery
157
1
Metabolex Inc
157
3
MorphoSys AG
159
1
Mundipharma International
159
1
Nippon Kayaku Co Ltd
160
1
Novartis
160
1
Ono Pharmaceutical Co Ltd
160
1
Pfizer
160
2
Pharmagenesis Inc
161
1
Regeneron Pharmaceuticals Inc
161
1
sanofi-aventis
161
3
Senju Pharmaceutical Co Ltd
163
1
SymBio Pharmaceuticals Ltd
163
2
Taiho Pharmaceuticals Co Ltd
164
1
Taisho Toyama Pharmaceutical Co Ltd
164
1
TAP Pharmaceutical Products Inc
164
1
Tercica Inc
165
1
Theravance Inc
165
2
Wyeth
166
1
XenoPort Inc
166
1
Zeria Pharmaceutical Co Ltd
167
1
APPENDIX 4-INFRASTRUCTURE
168
1
Research and Development Facilities
169
2
Manufacturing Facilities
170
2
APPENDIX 5-KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES
172
1
SUBSIDIARIES
172
3
JOINT VENTURES
175
1
Enter the keyword(s) which you would like to search for within this document and click "Search"
TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.
Price: $3,240.00
$
£
€
Following terms and conditions apply: All charges are made in USD.
Actual charge to your credit card may deviate due to the currency exchange
and Bank fees from your financial institution as some banks and credit cards impose fees for international transactions
outside the United States
. If you have any questions about these fees or the exchange rate applied to your booking, please contact your bank.
Close
Questions about
this research?
Send page to a friend
Return to
Alacra Company Snapshot
More Market Research
Search all our
Market Research
from one place.
Get FREE Research
Sign up here
to receive email alerts for
FREE Research
from Alacra Partners!
Can't Decide?
Purchasing premium research sight unseen can be intimidating. We want you to know what you are getting. Visit our
FAQ
or ask our
Customer Service Team
any questions about the report you are considering purchasing.
